Maternal care of undocumented pregnant women under the Fees Act (Medical) for Foreigners 1951. Perspectives of health and non-health actors
ForfatterLoo, Pei Shan
With the unprecedented international migration around the world, policies that restrict immigrants' health care access have become prevailing. In 2014, the amendment to The Fees Act (Medical) for Foreigners 1951 had further hindered the health care access of undocumented pregnant women. This qualitative study aimed to obtain perspectives of health and non-health actors regarding the implications of the amendment to the undocumented pregnant women. Ten semi-structured interviews were conducted in Kuala Lumpur, Malaysia. The findings show that Malaysians perceive as a threat when the competition for public health care access rises with the growing number of immigrants. The amendment was used to save the health care budget and to control the immigrant population. Scapegoating immigrants has nonetheless masked the weak governance and poor development of the health care system that has stretched the health care budget. The amendment is likely to show immediate cost saving. However, women are highly prone to various pregnancy complications without adequate maternal care, and may eventually result in increased hospital fees. The high medical cost will increase the difficulty in public health control as any outbreak of infectious disease can cost the government massive amounts of money. Also, provision of family planning services among the immigrants can directly improve maternal and child survival and extend women's work productivity from unwanted pregnancy. Stemming the undocumented immigrant pool not only can reduce job competition for Malaysia’s bottom 50%, the collected levy among the newly documented immigrants can in turn subsidies the health care services for immigrant group themselves. The presented findings are based on the perspectives from health and non-health actors in Malaysia. To conclude, this study shows a profound need for health and immigration policy reform. The effort is not just for the health of undocumented pregnant women, but most importantly for the economic and health benefit of Malaysians in general.
ForlagUiT Norges arktiske universitet
UiT The Arctic University of Norway
MetadataVis full innførsel
Følgende lisensfil er knyttet til denne innførselen:
Viser innførsler relatert til tittel, forfatter og emneord.
The Use of eHealth and Provider-Based Health Services by Patients with Diabetes Mellitus: Protocol for a Cross-Sectional Study Hansen, Anne Helen; Bradway, Meghan; Brož, Jan; Claudi, Tor; Henriksen, Øystein; Wangberg, Silje C; Årsand, Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-31)<b>Background:</b> The prevalence of diabetes and the use of electronic health (eHealth) resources are increasing. People with diabetes need frequent monitoring and follow-up of health parameters, and eHealth services can be of great significance in this regard. However, little is known about the extent to which different kinds of eHealth tools are used, and how the use of eHealth is associated ...
Cochrane Collaboration Systematic Reviews may be based on trials not approved by a research ethics committee Jokstad, Asbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-10-27)Systematic reviews (SR) may potentially contain reports of primary trials with ethical problems. The Cochrane Collaboration SRs are considered as the highest standard in evidence-based health care resources. All SRs completed during the last 5 years (2013–2017) under the management of the Oral Health Group of the Cochrane Collaboration were identified. All primary trials included in the Oral Health ...
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis Norum, Jan; Antonsen, Margaret Aarag; Tollåli, Geir; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin-Helene; Helbekkmo, Nina (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-29)1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients ...